Acute appearance of fatty acids in human plasma – a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males

Lipids in Health and Disease

Philip C Calder¹  Christa Zante³  Annette L West¹  Michael L Kagan² 

[1] Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, IDS Building, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK;Qualitas Health Ltd., 19 Hartom Street, P.O. Box 45423, Jerusalem 91450, Israel;MPS Hamburg GmbH, Kieler Strasse 99-105, Hamburg 22769, Germany

关键词: Phospholipids;    Glycolipids;    Polar lipids;    Krill oil;    Algal oil;    Docosahexaenoic acid;    Eicosapentaenoic acid;    Omega-3;   

Others  :  834539
DOI  :  10.1186/1476-511X-12-102

 received in 2013-06-26, accepted in 2013-07-11,  发布年份 2013

【 摘 要 】

Background

The long-chain n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have human health benefits. Alternatives to fish as sources of EPA and DHA are needed. Oil from the micro-algae Nannochloropsis oculata contains a significant amount of EPA conjugated to phospholipids and glycolipids and no DHA. Krill oil contains EPA and DHA conjugated to phospholipids. We compare the appearance of fatty acids in blood plasma of healthy humans after consuming a high fat meal followed by either algal oil or krill oil.

Methods

Ten healthy males aged 18-45 years consumed a standard high fat (55 g) breakfast followed by either algal oil (providing 1.5 g EPA and no DHA) or krill oil (providing 1.02 g EPA and 0.54 g DHA). All participants consumed both oils in random order and separated by 7 days. Blood samples were collected before the breakfast and at several time points up to 10 hours after taking the oils. Fatty acid concentrations (μg/ml) in plasma were determined by gas chromatography.

Results

Fatty acids derived mainly from the breakfast appeared rapidly in plasma, peaking about 3 hours after consuming the breakfast, and in a pattern that reflected their content in the breakfast. There were time-dependent increases in the concentrations of both EPA and DHA with both algal oil (P < 0.001 for EPA; P = 0.027 for DHA) and krill oil (P < 0.001 for both EPA and DHA). The concentration of EPA was higher with algal oil than with krill oil at several time points. DHA concentration did not differ between oils at any time point. The maximum concentration of EPA was higher with algal oil (P = 0.010) and both the area under the concentration curve (AUC) and the incremental AUC for EPA were greater with algal oil (P = 0.020 and 0.006). There was no difference between oils in the AUC or the incremental AUC for DHA.

Conclusion

This study in healthy young men given a single dose of oil indicates that the polar-lipid rich oil from the algae Nannochloropis oculata is a good source of EPA in humans.

【 授权许可】

   
2013 Kagan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Calder PC, Yaqoob P: Understanding omega-3 polyunsaturated fatty acids. Postgrad Med J 2009, 121:148-157.
• [2]Burdge GC, Calder PC: Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 2005, 45:581-597.
• [3]Dyerberg J, Bang HO: Haemostatic function and platelet poly unsaturated fatty acids in Eskimos. Lancet 1979, ii:433-435.
• [4]Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978, ii:117-119.
• [5]Mozaffarian D, Wu JH: Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
• [6]Mozaffarian D, Rimm EB: Fish in-take, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885-1899.
• [7]Schmidt EB, Arnesen H, de Caterina R, Rasmussen LH, Kristensen SD: Marine n-3 poly unsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 2005, 115:163-170.
• [8]Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB: Bioavailability of marine n-3 fatty acid formulations. Prostagland Leukotr Essent Fatty Acids 2010, 83:137-141.
• [9]Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA: Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010, 303:250-257.
• [10]Bucher HC, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002, 112:298-304.
• [11]Harris WS: n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 1996, 31:243-252.
• [12]Calder PC: Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 2011, 668:S50-S58.
• [13]Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Brit J Clin Pharmacol 2013, 75:645-662.
• [14]Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psych 2001, 159:477-479.
• [15]Sublette ME, Ellis SP, Geant AL, Mann JJ: Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psych 2011, 72:1577-1584.
• [16]Sinn N, Milte C, Howe PR: Oiling the brain: A review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2010, 2:128-170.
• [17]Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund L, Eriksdotter-Jönhagen M: Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiat 2008, 23:161-169.
• [18]Kris-Etherton P, Harris WS, Appel LJ, American Heart Association Nutrition Committee: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
• [19]Scientific Advisory Committee on Nutrition/Committee on Toxicity: Advice on fish consumption: Benefits and risks. London: TSO; 2004.
• [20]Gigliottia JC, Davenport MP, Beamera SK, Toua JC, Jaczynski J: Extraction and characterisation of lipids from Antarctic krill (Euphausia superba). Food Chem 2011, 125:1028-1036.
• [21]Yongmanitchai W, Ward OP: Screening of algae for potential alternative sources of eicosapentaenoic acid. Phytochem 1991, 30:2963-2967.
• [22]Mendes A, Reis A, Vasconcelos R, Guerra P, da Silva TL: Crypthecodinium cohnii with emphasis on DHA production: a review. J Appl Phycol 2009, 21:199-214.
• [23]Doughman SD, Krupanidhi S, Sanjeevi CB: Omega-3 fatty acids for nutrition and medicine: considering microalgae oil as a vegetarian source of EPA and DHA. Curr Diabetes Rev 2007, 3:198-203.
• [24]MacKenzie SA, Belcher LA, Sykes GP, Frame SR, Mukerji P, Gillies PJ: Safety assessment of EPA-rich oil produced from yeast: Results of a 90-day subchronic toxicity study. Reg Toxicol Pharmacol 2010, 58:490-500.
• [25]Winther B, Hoem N, Berge K, Reubsaet L: Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba. Lipids 2011, 46:25-36.
• [26]Küllenberg D, Taylor LA, Schneider M, Massing U: Health effects of dietary phospholipids. Lipids Health Dis 2012, 11:3. BioMed Central Full Text
• [27]Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C, Hahn A: Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis 2011, 10:145. BioMed Central Full Text
• [28]2008. http://www.accessdata.fda.gov/scripts/fcn/gras_notices/grn000242.pdf webcite
• [29]Sukenik A: Production of EPA from the eustigamatophyte Nannochloropsis. In Chemicals from Microalgae. Edited by Cohen Z. Boca Raton: CRC Press; 1999:41-53.
• [30]Schneider JC, Livne A, Sukenik A, Roessler PG: A mutant of nannochloropsis deficient in eicosapentaenoic acid production. Phytochem 1995, 40:807-814.
• [31]Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2001, 21:495-505.
• [32]Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatr 2002, 59:913-919.
• [33]Jacobson TA, Glickstein SB, Rowe JD, Soni PN: Effects of eicosapentaenoic acid and docosahexaenoic acid on low density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012, 6:5-18.
• [34]Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, Young S, Wang L, Jebb SA, Calder PC: Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012, 96:748-758.
• [35]Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KF: Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res 2003, 44:2065-2072.
• [36]Burdge GC, Powell J, Calder PC: Lack of effect of meal fatty acid composition on postprandial lipid, glucose and insulin responses in men and women aged 50-65 years consuming their habitual diets. Brit J Nutr 2006, 96:489-500.
• [37]Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KF: Dietary fatty acids make a rapid and substantial contribution to VLDL-triacylglycerol in the fed state. Am J Physiol Endocriniol Metab 2007, 292:E732-E739.
• [38]Gurr MI, Harwood JL, Frayn KN: Lipid Biochemistry. 5th edition. Oxford: Blackwell Science; 2002.
• [39]Burdge GC, Sala-Vila A, West AL, Robson HJL, Wilkinson Le Fevre L, Powell J, Calder PC: The effect of altering the 20:5n-3 and 22:6n-3 content of a meal on the postprandial incorporation of n-3 polyunsaturated fatty acids into plasma triacylglycerol and non-esterified fatty acids in humans. Prostagland Leukotr Essent Fatty Acids 2007, 77:59-65.
• [40]Arterburn LM, Hall EB, Oken H: Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006, 83:1467S-1476S.